United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 9

Name: Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 9 comparison snapshot
Creator: Fliar BI Prism

A five-company biological products, excluding disgnostic substances cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderTaysha Gene Therapies · 48

Strongest available pathRelay Therapeutics · -39.4%

Widest latest marginAziyo Biologics · 434.2%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1TSHA · Nasdaq

Taysha Gene Therapies

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2020Dallas, Texas$1.88B market cap

View full Companies Radar profile

48Cautious

Snapshot price$5.77as of page date

Monthly-close return-70.0%five-year window

FY2025 revenue$0.01BTaysha Gene Therapies, Inc.

Net margin-1115.3%FY2025

P/E snapshot-12.1xone ratio, not a verdict

Prism attention21.3%share across these five

Filing track recordRevenue, USD billions

+290.6%

FY2022–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 57.5%

52-week position67% through range

$2.71$7.30

News mentions714

Community mentions5partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 8/100higher means more observed risk

Earnings signal60/100
Management stability90/100
Market position3/100
Capital-event signal75/100
Innovation pulse16/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 8 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 3 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2LCTX · NYSE

Lineage Cell Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1990Carlsbad, California$280.7M market cap

View full Companies Radar profile

37Cautious

Snapshot price$1.11as of page date

Monthly-close return-54.0%five-year window

FY2025 revenue$0.01BLineage Cell Therapeutics, Inc.

Net margin-436.5%FY2025

P/E snapshot-10.9xone ratio, not a verdict

Prism attention26.7%share across these five

Filing track recordRevenue, USD billions

+235.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 35.3%

52-week position10% through range

$1.00$2.09

News mentions893

Community mentions18partial coverage

U.S.-scope patents99

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal50/100
Management stability90/100
Market position3/100
Capital-event signal25/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3TCRX · Nasdaq

TScan Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1995Boston, Massachusetts$49.2M market cap

View full Companies Radar profile

36Cautious

Snapshot price$0.75as of page date

Monthly-close return-91.6%five-year window

FY2025 revenue$0.01BTScan Therapeutics, Inc.

Net margin-1256.8%FY2025

P/E snapshot-0.8xone ratio, not a verdict

Prism attention13.5%share across these five

Filing track recordRevenue, USD billions

+1.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.5%

52-week position2% through range

$0.72$2.57

News mentions454

Community mentions3partial coverage

U.S.-scope patents162

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal45/100
Management stability90/100
Market position0/100
Capital-event signal30/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4ELUT · Nasdaq

Aziyo Biologics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2015Silver Spring, Maryland$39.0M market cap

View full Companies Radar profile

34Cautious

Snapshot price$0.88as of page date

Monthly-close return-89.3%five-year window

FY2025 revenue$0.01BELUTIA INC.

Net margin434.2%FY2025

Prism attention13.7%share across these five

Filing track recordRevenue, USD billions

-74.1%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -28.6%

52-week position20% through range

$0.50$2.38

News mentions461

Community mentions0partial coverage

U.S.-scope patents7

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal26/100
Management stability90/100
Market position6/100
Capital-event signal40/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5RLAY · Nasdaq

Relay Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2016Cambridge, Massachusetts$4.11B market cap

View full Companies Radar profile

31Cautious

Snapshot price$18.77as of page date

Monthly-close return-39.4%five-year window

FY2025 revenue$0.01BRelay Therapeutics, Inc.

Net margin-1800.6%FY2025

P/E snapshot-11.4xone ratio, not a verdict

Prism attention24.8%share across these five

Filing track recordRevenue, USD billions

+406.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 50.1%

52-week position86% through range

$3.57$21.27

News mentions832

Community mentions21partial coverage

U.S.-scope patents234

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal21/100
Management stability90/100
Market position0/100
Capital-event signal46/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Relay Therapeutics

-39.4%

Lineage Cell Therapeutics

-54.0%

Taysha Gene Therapies

-70.0%

Aziyo Biologics

-89.3%

TScan Therapeutics

-91.6%

Latest revenue

USD billions, official filing scope shown on each company card.

Lineage Cell Therapeutics

$0.01B

Relay Therapeutics

$0.01B

Aziyo Biologics

$0.01B

Taysha Gene Therapies

$0.01B

TScan Therapeutics

$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Aziyo Biologics

434.2%

Lineage Cell Therapeutics

-436.5%

Taysha Gene Therapies

-1115.3%

TScan Therapeutics

-1256.8%

Relay Therapeutics

-1800.6%

Prism news attention

Normalized share across these five names; attention is not quality.

Lineage Cell Therapeutics

26.7%

Relay Therapeutics

24.8%

Taysha Gene Therapies

21.3%

Aziyo Biologics

13.7%

TScan Therapeutics

13.5%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Lineage Cell Therapeutics leads the conversation

It holds 26.7% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.01B.

Price path

Relay Therapeutics leads the available price paths

Its monthly-close return is -39.4% for the five-year window. At the other end, TScan Therapeutics is -91.6% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Aziyo Biologics has the widest latest margin

Its FY2025 net margin is 434.2%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Taysha Gene Therapies shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -12.1x while its five-year window price return is -70.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · LCTX

Lineage Cell Therapeutics

893available Prism news records

Prism top themes

Capital allocation & transactions

Earnings & financial performance

Leadership & governance

Price action & investor response

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+40.4%132 latest 12m vs 94 prior 12m

Machine-classified coverage tone

99.1% positive-0.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stem cell banking 62cell-based therapies 55cell therapy 35stem cell transplantation 29somatic cell therapy 11gene therapy rare diseases 10pluripotent stem cells 10biotherapeutics 9

Keyword tag occurrences in available Prism news records.

Coverage: 2010-07-19–2026-05-27 · trend and themes shown through 2026-05

Areas of research · RLAY

Relay Therapeutics

832available Prism news records

Prism top themes

Price action & investor response

Capital allocation & transactions

Legal, arbitration & regulatory

Earnings & financial performance

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-21.1%168 latest 12m vs 213 prior 12m

Machine-classified coverage tone

95.1% positive+2.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

machine learning drug discovery 22neural networks drug design 20angiogenesis inhibitors 19her2-targeted therapy 14parp inhibitors breast cancer 13neoadjuvant therapy breast cancer 12cancer biomarkers 11chemotherapy breast cancer 11

Keyword tag occurrences in available Prism news records.

Coverage: 2014-02-04–2026-06-18 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

TSHA

Taysha Gene Therapies

through 2026-04-18

Company announcements 14Earnings releases 9Listing / IPO 2Regulatory 2

2026-04-18
Listing / IPO
Taysha Gene Therapies completed its initial public offering in May 2021.
2026-04-03
Company announcements
today announced that, on April 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 300,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment.
2026-01-05
Earnings releases
Based on Taysha Gene Therapies’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $32.73 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LCTX

Lineage Cell Therapeutics

through 2025-10-31

Earnings releases 22Company announcements 1Leadership changes 1

2025-10-31
Earnings releases
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, following the close of the U.S. financial markets.
2024-04-01
Leadership changes
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.
2023-05-22
Company announcements
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that the Company is expected to be added to the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective as of the U.S. market open on June 26, 2023, according to a preliminary list of additions posted to the FTSE Russell website.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TCRX

TScan Therapeutics

through 2025-03-14

Leadership changes 6Company announcements 2Earnings releases 2

2025-03-14
Earnings releases
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TScan Therapeutics $2.82 million 33.93 -$89.22 million ($1.15) -1.56 Novavax $682.16 million 1.93 -$545.06 million ($1.33) -6.14
2024-04-24
Company announcements
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the underwriters of its previously announced public offering, which closed on April 19, 2024, have partially exercised their over-allotment option to purchase an additional 2,485,487 shares of its voting common stock at the public offering price of $7.13 per share, less underwriting discounts and commissions. After giving effect to the option closing, the total number of shares sold by the Company in the offering were 4,958,068 shares, which along with pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of its voting common stock, resulted in aggregate gross proceeds to the Company of approximately $167.8 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
2024-01-29
Leadership changes
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Jason A. Amello as Chief Financial Officer.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ELUT

Aziyo Biologics

through 2023-05-10

Earnings releases 7

2023-05-10
Earnings releases
Net sales for the first quarter of 2023 were $13.1 million, an increase of 14% compared to the first quarter of 2022.
2023-05-03
Earnings releases
today announced that it will release its first quarter 2023 financial results after market close on Wednesday, May 10, 2023.
2023-03-22
Earnings releases
Net sales for the full year 2022 were $49.2 million, an increase of 4% compared to the full year 2021 net sales of $47.4 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RLAY

Relay Therapeutics

through 2025-11-06

Earnings releases 13Business contracts 2Leadership changes 1

2025-11-06
Earnings releases
Net loss was $74.1 million for the third quarter of 2025, or a net loss per share of $0.43.
2025-06-06
Leadership changes
The stockholders elected Alexis Borisy and Mark Murcko, Ph.D., as class II directors for a three-year term.
2025-06-04
Business contracts
On June 3, 2025, Relay Therapeutics, Inc. announced a lease amendment with ARE MA Region No. 58, LLC, which will accelerate the termination of its Binney Street Lease in Cambridge, Massachusetts. This strategic move involves transitioning to a smaller office space at Kendall Square, resulting in a significant reduction of approximately $16 million in rent expenses over the lease commitments.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence

2020 extracted base$194.20B–$477.15B

2033 extracted forecast$685.30B–$1.37T

Implied source CAGR8.5%

high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records

Latest 12m volume+9.8%10786 vs 9825 records

Positive classified tone41.7%+4.6 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies

4,078

substance abuse education

3,736

opioid addiction and treatment

3,643

overdose prevention techniques

3,482

controlled substance regulations

3,381

substance abuse overdose fatalities

3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576cannabis policy reform discussions 1,328psychedelic mental health studies 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 41–48. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Taysha Gene Therapies leads the readiness ranking

Its Prism readiness score is 48/100, the highest in this five-company comparison.

Open Taysha Gene Therapies in Companies Radar

Scale and margin leadership sit with Relay Therapeutics and Aziyo Biologics

Relay Therapeutics has the largest displayed latest revenue at $0.01B; Aziyo Biologics has the widest displayed latest margin at 434.2%.

Open Relay Therapeutics in Companies Radar Open Aziyo Biologics in Companies Radar

Comparisons

Strongest versus weakest available price path

Relay Therapeutics is -39.4% for its five-year window; TScan Therapeutics is -91.6% for its five-year window.

Open Relay Therapeutics in Companies Radar Open TScan Therapeutics in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.01B for Relay Therapeutics to $0.01B for TScan Therapeutics. Entity and filing-period labels remain visible on the company cards.

Open Relay Therapeutics in Companies Radar Open TScan Therapeutics in Companies Radar

Anomalies

Relay Therapeutics has the widest attention-readiness rank gap

It ranks #2 by measured news attention (24.8%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Relay Therapeutics in Companies Radar

Relay Therapeutics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +406.9% while its available monthly-close return is -39.4%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Relay Therapeutics in Companies Radar

Explanations

Attention measures coverage volume, not quality

Lineage Cell Therapeutics's 26.7% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Lineage Cell Therapeutics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Taysha Gene Therapies's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 48/100 score.

Open Taysha Gene Therapies in Companies Radar

Stress-test the largest divergence before forming a view

Compare Relay Therapeutics's profile with Relay Therapeutics's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Relay Therapeutics in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.